GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (OTCPK:NAVB) » Definitions » Long-Term Debt

Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Long-Term Debt

: $0.00 Mil (As of Sep. 2023)
View and export this data going back to 1992. Start your Free Trial

Navidea Biopharmaceuticals's Long-Term Debt for the quarter that ended in Sep. 2023 was $0.00 Mil.

Navidea Biopharmaceuticals's quarterly Long-Term Debt declined from Mar. 2023 ($1.96 Mil) to Jun. 2023 ($0.00 Mil) but then stayed the same from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

Navidea Biopharmaceuticals's annual Long-Term Debt stayed the same from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) but then increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($1.87 Mil).

Navidea Biopharmaceuticals Long-Term Debt Historical Data

The historical data trend for Navidea Biopharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Long-Term Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 1.87

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Long-Term Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 1.87 1.96 - -

Navidea Biopharmaceuticals  (OTCPK:NAVB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Navidea Biopharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (OTCPK:NAVB) » Definitions » Long-Term Debt
Comparable Companies
KRBP CMND CYTO PXMD ARDS TSOI ONCO SNPX WINT KTRA OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
N/A
Address
4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Website
https://www.navidea.com
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Executives
Craig Dais officer: Chief Financial Officer 4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017
Dana J Moss director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jill Stefanelli director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Josh M Wilson director 4795 BRADENTON AVE, STE 240, DUBLIN OH 43017
Scott John K Jr. director, 10 percent owner 30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121
Agnieszka Winkler director C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281
Thomas F Farb director C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116
Michel Mikhail officer: Chief Regulatory Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Malcolm G Witter director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Alexander L Cappello director C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301
Amit Bhalla director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Joel H. Kaufman officer: Chief Business Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jed Latkin officer: Interim COO 152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552